The meeting presented findings on effective treatments for various pet skin conditions and insights into the immune responses of dogs with atopic dermatitis.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the AmericanAcademy of Dermatology Annual Meeting in 2026.
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.
In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.
A 28-year-old experienced hair loss and found success with daily 1mg Finasteride, noticing thicker hair without side effects. Despite this, their dermatologist suggested switching to expensive peptide serums, prompting the individual to seek a second opinion on long-term Finasteride and oral Minoxidil use.